Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-08-02
2005-08-02
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388220, C530S388800, C530S391300, C435S069100, C435S069700, C435S328000, C435S344000
Reexamination Certificate
active
06924359
ABSTRACT:
Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.
REFERENCES:
patent: 4752569 (1988-06-01), Terasaki et al.
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4865998 (1989-09-01), Feickert et al.
patent: 4959318 (1990-09-01), Foster et al.
patent: 4997762 (1991-03-01), Hanna, Jr. et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5288629 (1994-02-01), Berkner
patent: 5428130 (1995-06-01), Capon et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5516650 (1996-05-01), Foster et al.
patent: 5541087 (1996-07-01), Lo et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5759808 (1998-06-01), Casterman et al.
patent: 5788965 (1998-08-01), Berkner et al.
patent: 5800988 (1998-09-01), Casterman et al.
patent: 5817788 (1998-10-01), Berkner et al.
patent: 5824639 (1998-10-01), Berkner
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5840526 (1998-11-01), Casterman et al.
patent: 5840844 (1998-11-01), Lasky et al.
patent: 5861374 (1999-01-01), Berkner et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5879672 (1999-03-01), Davis et al.
patent: 5939530 (1999-08-01), Gelboin et al.
patent: 5969107 (1999-10-01), Carceller et al.
patent: 6001978 (1999-12-01), Edgington et al.
patent: 6005079 (1999-12-01), Casterman et al.
patent: 6015695 (2000-01-01), Casterman et al.
patent: 6017514 (2000-01-01), Epstein et al.
patent: 6039944 (2000-03-01), Berkner et al.
patent: 6132729 (2000-10-01), Thorpe et al.
patent: 6140470 (2000-10-01), Garen et al.
patent: 6406697 (2002-06-01), Capon et al.
patent: 6448071 (2002-09-01), Schneck et al.
patent: 6541610 (2003-04-01), Smith
patent: 6555319 (2003-04-01), Wong et al.
patent: 6572852 (2003-06-01), Smith et al.
patent: WO 99/14430 (1990-11-01), None
patent: WO-93/17715 (1993-09-01), None
patent: WO 94/26787 (1994-11-01), None
patent: WO-96/01653 (1996-01-01), None
patent: WO-98/31394 (1998-07-01), None
Cruse et al. Illustrated Dictionary of Immunology, CRC Press, p. 109, 1995.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, 1982.
Lederman et al. Molecular Immunology 28:1171-1181, 1991.
Li et al. Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980.
Coleman P. M. Research in Immunology, 145:33-36, 1994.
Nakagaki et al. Biochemistry, 30(45):10819-10824, 1991.
Olson et al. International Journal of Cancer, 73:865-870, 1997.
Drake et al. American Journal of Pathobiology, 134(5):1087-1097,1989.
Contrino et al. Nature Medicine, 2:209-215, 1996.
Dickinson et al. Proc. Natl. Acad. Sci, USA, 93:14379-14384, 1996.
Min et al. Cancer Research, 56:2428-2433, 1996.
Wang et al., PNAS 96:1627-32, 1999.
Kimura et al., “The Potential of Active Drug Targeting with Immunoconjugates to Choroidal Neovascularization”, IOVS, vol., 41, No. 4, Mar. 15, 2000, p. S180.
Gewolb, J. “New Cancer Therapy Kills Blood Vessels,”Science On Line, Oct. 1, 2001. http://www.iconictherapeutics.com/SCIENCE01.pdf.
“Molecule May Kill Cancer Tumors,”The Associated Press, Oct. 1, 2001. http://www.iconictherapeutics.com/APx01.pdf.
Schubert, Charlotte, “Medding in macular degeneration,”Nature Medicine, Apr. 2003. vol. 9, No. 4, p. 396.
Dal Porto et al., “A soluble divalent class I major hisocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations”,Proc. Natl., Acad. Sci USA, Jul. 1993, pp. 6671-6675, vol. 90.
Eilat et al., “Secretion of a soluble, chimeric γδ T-cell receptor-immunoglobulin heterodimer”,Proc. Natl. Acad. Sci. USA, Aug. 1992, pp. 6871-6875, vol. 89.
Gregoire et al., “Engineered secreted T-cell receptor αβ heterodimers”,Proc. Natl. Acad. Sci. USA, Sep. 1991, pp. 8077-8081, vol. 88.
Mohler et al., “Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists”,J. Immunol., Aug. 1993, pp. 1548-1561, vol. 151, No. 3.
Erben et al., “Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells”,Cancer Res., Jun. 1999, pp. 2924-2930, vol. 59, No. 12 (Abstract only).
Baba, E., “Effects of IgC-Fc-mitomycin C conjugate on cancer cells”,Hokkaido Igaku Zasshi, Mar. 1996, pp. 271-281, vol. 71, No. 2 (Article in Japanese; abstract only).
Peppel et al., “A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity”,J. Exp. Med., Dec. 1991, pp. 1483-1489, vol. 174, No. 6. (Abstract only).
E. Wilmes et al., “Versuche zur Herstellung menschlicher monoklonaler Antikorper gegen Melanome unter Verwendung zervikaler Lymphknoten,”Laryng. Rhinol. Otol., (1987), vol. 66, pp. 144-148.
Jamie K. Scott and George Smith, “Searching for Peptide Ligands with an Epitope Library,”Science, (Jul. 27, 1990). vol. 249, pp. 386-390.
James D. Marks et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage,”J. Med. Biol., (1991), vol. 222, pp. 581-597.
Greg Winter and Cesar Milstein, “Man-made Antibodies,”Nature, (Jan. 24, 1991), vol. 349, pp. 293-299.
James D. Marks et al., By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,Bio/Technology, (Jul. 1992), vol. 10, pp. 779-783.
G. Del Bino et al., “Apoptotic Cell Death Triggered by Camptothecin or Tenipos.de. The Cell Cycle Specificity and Effects of Ionizing Radiation,”Cell Prolif., (1992), vol. 25, pp. 537-548.
Andrew D. Griffiths et al., “Human Anti-self Antibodies with High Specificity from Phage Display Libraries,”The EMBO Journal, (1993), vol. 12, No. 2, pp. 725-734.
Lee H. Pai and Ira Pastan, “Immunotoxin Therapy for Cancer,”JAMA, (Jan. 6, 1993), vol. 269, No. 1, pp. 78-81.
Dave S.B. Hoon et al., “Molecular Cloning of a Human Monoclonal Antibody Reactive to Ganglioside Antigen on Human Cancers,”Cancer Research, (Nov. 1, 1993), vol. 53, pp. 5244-5250.
Maria-Ana Ghetie and Ellen S. Vitetta, “Recent Developments in Immunotoxin Therapy,”Current Opinion in Immunology, (1994), vol. 6, pp. 707-714.
Brenda L. Hall et al., “Establishment, Molecular Rescue, and Expression of 123AV16-1, a Tumor-reactive Human Monoclonal Antibody,”Cancer Research, (1994), vol. 54, pp. 5178-5185.
Xiaohong Cai and Alan Garen, “Anti-melanoma Antibodies from Melanoma Patients Immunized with Genetically Modified Autologous tumor cells: Selection of Specific Antibodies from Single-Chain Fv Phage Fusion Libraries,”Proc. Natl. Acad. Sci. USA, (1995), vol. 92, pp. 6537-6541.
Martin Friedlander et al., “Involvement of Integrins αvβ3and αvβ5in Ocular Neovascular Diseases,”Proc. Natl. Acad. Sci. USA, (Sep., 1996), vol. 93, pp. 9764-9769.
Xiaohong Cai and Alan Garen, “A Melanoma-Specific VHAntibody Cloned from a Fusion Phage Library of a Vaccinated Melanoma Patient,”Proc. Natl. Acad. Sci. USA, (Jun. 1996), vol. 93, pp. 6280-6285.
Craig D. Dickinson, “Iden
Garen Alan
Hu Zhiwei
Banner & Witcoff, LTD.
Blanchard David J.
Helms Larry R.
Yale University
LandOfFree
Neovascular-targeted immunoconjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neovascular-targeted immunoconjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neovascular-targeted immunoconjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3522869